DelMar Pharmaceuticals Inc. recently presented new data in a research poster called, “Activity of dianhydrogalactitol (VAL-083) in ovarian tumor models, sensitive or resistant to cisplatin” at the 11th Biennial Ovarian Cancer Research Symposium.
"We were pleased to present these data, which are highly supportive of VAL-083's potential as a new therapeutic option for ovarian cancer patients whose treatment is underserved by currently available therapy,” DelMar CEO Jeffrey Bacha said. “We plan to work with our advisors to develop a strategy to advance VAL-083 into clinical trials for the treatment of ovarian cancer, either as a single-agent or in combination with other approved agents.”
The data was presented yesterday at the Rivkin Center for Ovarian Cancer in Seattle, Washington. The research was presented with its collaborators from the University of Texas MD Anderson Cancer Center.
"These data are important because they provide further support of our previous research suggesting that VAL-083 imparts its anti-cancer activity via double-strand breaks as a result of DNA cross-links at the N7-position of guanine,” DelMar CSO Dr. Dennis Brown said. “Homologous recombination is the mechanism generally employed by cells to repair damage resulting from DNA double strand breaks. Deficiencies in HR are a hallmark of many cancers, including ovarian cancers, while normal cells retain HR function. This may explain why VAL-083 has been observed to possess high activity against cancer yet exhibit limited toxicity against normal cells."